Falco Holdings Co., Ltd. (4671) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Falco Holdings Co., Ltd. (4671:JPX), powered by AI.

Current Price
¥2,565
P/E Ratio
14.1
Market Cap
27.1B
Sector
Healthcare
What is the Falco Holdings Co., Ltd. stock price forecast?

Falco Holdings Co., Ltd. is currently trading at ¥2,565. View real-time AI analysis on Alpha Lenz.

What is Falco Holdings Co., Ltd. insider trading activity?

View the latest insider trading data for Falco Holdings Co., Ltd. on Alpha Lenz.

What is Falco Holdings Co., Ltd.'s P/E ratio?

Falco Holdings Co., Ltd.'s P/E ratio is 14.1.

Falco Holdings Co., Ltd.

JPX · 4671
¥2,565-8(-0.31%)Market closedJPX regular session 09:00–15:00 JST
Ask about Falco Holdings Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Falco Holdings Co., Ltd. trades at a P/E of 14.1 (undervalued) with modest ROE of 7.5%.

Ask for details

Company Overview

Falco Holdings Co., Ltd. is a company engaged in providing comprehensive diagnostic services across multiple sectors, primarily focusing on the healthcare and medical industries. The company's core function revolves around clinical laboratory testing and diagnostic analysis, which are critical components in the detection, diagnosis, and management of various diseases. Falco Holdings supports hospitals, clinics, and healthcare providers by delivering precise and timely diagnostic results, thereby playing an indispensable role in patient care and treatment planning. With a wide range of laboratory services, Falco Holdings Co., Ltd. is instrumental in enhancing the accuracy and efficiency of medical diagnostics. The company's offerings include molecular diagnostics, pathology testing, and preventive health screenings, all of which are crucial in the early detection and monitoring of health conditions. By leveraging advanced technological capabilities and a thorough understanding of medical science, Falco Holdings contributes significantly to the healthcare sector's sustainability and operational effectiveness. In the financial market, the company serves as a prominent entity reflecting the healthcare industry's growth and technological advancements, underlining the importance of innovation and precision in the evolving landscape of medical diagnostics.

CEOMr. Tadashi Yasuda
SectorHealthcare
IndustryDiagnostics & Research
Employees1,062

Company Statistics

FY 2025

Profile

¥27,087,618,375Market Cap
¥43,313,000,000Revenue
0.00Shares Out
1,062Employees

Margins

30.84%Gross
8.04%EBITDA
5.39%Operating
6.41%Pre-Tax
4.43%Net

Valuation

14.11P/E
1.07P/B
0.63EV/Sales
5.49EV/EBITDA
23.93P/FCF

Growth (CAGR)

-4.68%Rev 3Yr
0.06%Rev 5Yr
-24.82%Op Inc 3Yr
22.66%Op Inc 5Yr
-18.39%Net Inc 3Yr
9.09%Net Inc 5Yr

Returns

5.30%ROA
7.49%ROE
7.68%ROIC

Financial Health

¥9,420,000,000Cash & Cash Equivalents
¥1,347,000,000Net Debt
42.64%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Falco Holdings Co., Ltd. (ticker: 4671) is a company listed on JPX in the Healthcare sector (Diagnostics & Research). It has approximately 1,062 employees. Market cap is $27.1B.

The current price is 2,565 with a P/E ratio of 14.11x and P/B of 1.07x.

ROE is 7.49% and operating margin is 5.39%. Annual revenue is $43.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Falco Holdings Co., Ltd. (4671) Stock Forecast 2026 ¥2,565 — Price, Financials & Analyst Targets | Alpha Lenz